To include your compound in the COVID-19 Resource Center, submit it here.

ASCO abstract details Tarceva improvement in EURTAC trial

First-line treatment with Tarceva erlotinib in advanced non-small cell lung cancer (NSCLC) led to a median progression-free survival of 9.4

Read the full 203 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE